Acute infectious and chronic diarrheal diseases are important public health problems. A recent study by Fiskerstrand and colleagues identi ed a family with a rare early onset familial diarrhea. By linkage analysis and exon sequencing, the authors identi ed a heterozygous missense mutation in GUCY2C, encoding the guanylate cyclase C receptor, which is involved in intestinal secretion. This newly identi ed gene in the etiology of a familial diarrhea provides a candidate target for the development not only of new treatments for diarrhea, but also of a new drug class to treat constipation.
Diarrhea, caused by acute infectious or chronic diseases, may be considered as an imbalance between the approximately 7 l of fluids ingested or secreted into the gastrointestinal tract each day, and the reabsorption of almost an equivalent volume. Such an imbalance may lead to malabsorption of nutrients, dehydration and electrolyte imbalances. Infectious organisms such as Escherichia coli or Vibrio cholerae produce toxins that stimulate normal secretory pathways in the intestine, resulting in potentially life-threatening secretory diarrhea and dehydration.
e gold standard of treatment is rehydration with glucose-electrolyte solution but, regrettably, there is still a high mortality from these conditions in developing countries; hence, more effective treatments are needed.
Intestinal secretion may result from stimulation of a number of secretory pathways. For example, V. cholerae infection induces enteroendocrine cells to secrete 5-hydroxy tryptamine (5-HT or serotonin), which stimulates secretion of water and electrolytes from small intestinal epithelial cells or enterocytes [1] . In addition, cholera is associated with outpouring of mucin from goblet cells. It has been shown that secretions from goblet cells include the peptides guanylin [2] and uroguanylin, which have similar amino acid sequences to the heat-stable enterotoxin of E. coli. ese enterotoxins and endogenous peptides bind to guanylate cyclase C (GC-C) and stimulate the production of increased levels of intracellular cyclic guanosine monophosphate (cGMP). Increased levels of cGMP ultimately activate the secretion of chloride ions through the cystic fibrosis transmembrane conductance regulator (CFTR). When chloride reaches the intestinal lumen, its osmotic force pulls water out of the interstitial fluid through the spaces between enterocytes and this ultimately leads to dehydration.
It has been demonstrated that enterotoxigenic E. coli requires the GC-C receptor to induce intestinal secretion [3] . In addition to its presence in goblet cells, guanylin is also located in enteroendocrine cells, as well as in neuro endocrine tumors such as carcinoids. In fact, enhanced local secretion of guanylin may contribute to secretory diarrhea in these patients [4] . e relationship of enterocytes, goblet cells and enteroendocrine cells in the lining of the intestine and the role of secretomotor mechanisms has been reviewed previously [5] . Although some of the signaling pathways involved in abnormal intestinal secretion have been identified, targeted approaches to reverse secretion are needed to complement rehydration therapy.
is article highlights a recent study that identifies the molecular genetic basis of a familial diarrhea (FD), illustrating a mechanism that can be pharmacologically targeted to enhance secretion in constipation or to inhibit secretion in diarrheal diseases.
Diarrhea due to mutation in GUCY2C
Fiskerstrand et al. [6] identified a Norwegian family with a rare, early onset form of chronic or intermittent FD. Their investigation started with careful clinical obser vations of an 88yearold admitted to hospital for acute diarrhea and dehydration. It was noted that affected members of the family started to develop symptoms in infancy, had chronic, relatively mild diarrhea, and the symp toms tended to subside by middle age in some members of the family. The FD was a dominantly inherited, fully penetrant disease in 32 (18 male and 14 female) members of the family. Fourteen unaffected members of the family were also evaluated.
In a series of elegant studies, the authors used whole genome linkage analysis based on arrays with SNPs to identify a candidate region on chromosome 12, and then sequenced GUCY2C, encoding GCC. Linkage analysis was used to determine the candidate region for the mutation in samples from 11 affected members and 14 unaffected members. This analysis revealed only one shared region in the affected members, located on the short arm of chromosome 12 (12p) with a maximum LOD (logarithm (base 10) of odds) score of 5.1. A haplotype spanning approximately 2.9 megabases showed complete segregation with the disease, and the region contained 28 putative protein coding genes, including GUCY2C. Sequence analysis identified a heterozygous base substitution, c.2519G→T, in exon 22. This SNP was identified in all affected family members. Exome sequen cing of the entire candidate region from three affected family members excluded mutations in genes other than GUCY2C as possible causes of or contributors to suscepti bility to the disease.
In addition, Fiskerstrand et al. [6] conducted functional studies of mutant GCC in HEK293T cells. Exposure of the mutant receptor to its ligands (heatstable entero toxin, uroguanylin and guanylin) resulted in markedly increased (up to eightfold) production of cGMP. These functional assays demonstrate that the mutation is capable of inducing the intracellular production of the second messenger cGMP, which results in intestinal secretion through CFTR.
The authors appropriately describe this familial variation as a form of 'genetic knockin' of the mechanism that is stimulated by enterotoxigenic E. coli, and this represents an intriguing confluence of the effects of bugs and genes.
clinical significance
The Fiskerstrand et al. study [6] , which identified the causative GUCY2C mutation, has important implications from mechanistic, diagnostic and therapeutic perspec tives. First, identification of this gene mutation in FD provides evidence that the pathway is an important mechanism of chronic diarrhea in addition to infectious enterotoxic diarrhea. Second, mutation in GUCY2C should be considered in the differential diagnosis of chronic diarrhea, especially when there is a positive history of FD. Third, understanding the pathway provides a target for the development of a new drug class to treat constipation by inducing intestinal secretion. Since analogs of guanylin and uroguanylin (linaclotide and plecanatide [7, 8] ) already exist, clinical translation of the science to develop secretagogue drugs for relief of constipation and associated symptoms (bloating and abdominal pain) had preceded the intriguing molecular genetic discovery of Fiskerstrand et al. [6] . Targeting the receptor represents an alternative therapeutic approach, in lieu of targeting the gene itself.
However, there are some loose ends in the story. The susceptibility of the Norwegian family to inflammatory bowel disease (IBD), small bowel obstruction and esophagitis in the absence of hiatal hernia cannot be easily attributed to the effects of the GUCY2C mutation on GCC, based on current knowledge. In addition, there are no reports of any association of the GUCY2C muta tion and IBD, even with genomewide association studies [9, 10] . Nevertheless, the GCC agonists plecanatide and SP333 (analogs of uroguanylin) have been shown to ameliorate inflammation in murine colitis models via downregulation of certain proinflammatory cytokines, such as IL6, IL17 and IL23 [9] , and they may also have therapeutic potential in IBD and, possibly, carcinogenesis [8] .
This remarkable story may eventually have a happy ending for patients with this specific FD. The report should stimulate the development of blockers of the GC C and CFTR intestinal secretory pathways, and this will have potential for wide application to lifethreatening infectious diarrheas, in addition to the chronic, mild, nonfatal diarrhea afflicting this family; these diarrheas could then be specifically targeted with personalized or precision medicine.
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